110.54
price down icon0.29%   -0.32
after-market Handel nachbörslich: 110.51 -0.03 -0.03%
loading

Novartis Ag Adr Aktie (NVS) Neueste Nachrichten

pulisher
Apr 21, 2025

Gastric Neuroendocrine Tumors Market Report 2025 | Advancements in Diagnostics Propel Early Detection of gNETs - GlobeNewswire Inc.

Apr 21, 2025
pulisher
Apr 11, 2025

Swiss pharmaceutical giant announces plans for $1.1B campus in San Diego - fox5sandiego.com

Apr 11, 2025
pulisher
Apr 11, 2025

Stocks to Watch Friday: JPMorgan, Wells Fargo, BlackRock, Newmont - WSJ

Apr 11, 2025
pulisher
Apr 04, 2025

Pharma Stock Roundup: FDA Nod To SNY, AZN & NVS, JNJ Talc Suits Failure - Barchart.com

Apr 04, 2025
pulisher
Apr 03, 2025

FDA Grants Accelerated Approval To NVS Kidney Disease Drug - Barchart.com

Apr 03, 2025
pulisher
Apr 03, 2025

Quantum Corp’s Banking’s 100-Day Moving Average at 21.57: Will the Stock Break Through? - investchronicle.com

Apr 03, 2025
pulisher
Mar 27, 2025

Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth - Morningstar

Mar 27, 2025
pulisher
Mar 26, 2025

No room on the ARK? - Morningstar

Mar 26, 2025
pulisher
Mar 25, 2025

5 Large Drug Stocks To Watch As Industry Recovers - Barchart

Mar 25, 2025
pulisher
Mar 21, 2025

FDA Approves Novartis Drug For Rare Kidney Disease Treatment - Barchart

Mar 21, 2025
pulisher
Mar 19, 2025

Novartis scraps use of diverse panels for hires in US - Reuters

Mar 19, 2025
pulisher
Mar 14, 2025

Alnylam Rallies 62% In A Year: Can The Stock Maintain This Momentum? - Barchart

Mar 14, 2025
pulisher
Mar 13, 2025

Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.

Mar 13, 2025
pulisher
Mar 12, 2025

Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.

Mar 12, 2025
pulisher
Mar 07, 2025

Alberta sets a new standard for advanced prostate cancer treatment with public reimbursement of Pluvicto™ - Barchart

Mar 07, 2025
pulisher
Mar 07, 2025

Giovanni Caforio, M.D. - Novartis

Mar 07, 2025
pulisher
Mar 05, 2025

Novartis Near Buy Point; Earns Near-Best Overall Rating - Investor's Business Daily

Mar 05, 2025
pulisher
Mar 04, 2025

META_TITLE_QUOTE - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Novartis Earnings Surprised The Street; Still Going Strong - Investor's Business Daily

Mar 04, 2025
pulisher
Mar 03, 2025

Novartis Gets CHMP Opinion for Label Expansion of Fabhalta - Yahoo Finance

Mar 03, 2025
pulisher
Feb 26, 2025

AZN: 3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine - StockNews.com

Feb 26, 2025
pulisher
Feb 25, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Feb 25, 2025
pulisher
Feb 21, 2025

NVS: 3 Gene Therapy Stocks With Game-Changing Potential - StockNews.com

Feb 21, 2025
pulisher
Feb 18, 2025

NVS Quantitative Stock Analysis - Nasdaq

Feb 18, 2025
pulisher
Feb 16, 2025

Novartis: Strong Execution With A P/E Discount (NYSE:NVS) - Seeking Alpha

Feb 16, 2025
pulisher
Feb 13, 2025

Company’s Banking Stock: Dissecting a 2.21% Quarterly Revenue Decline Amid Growth - The InvestChronicle

Feb 13, 2025
pulisher
Feb 13, 2025

Novartis receives Health Canada approval for Fabhalta® oral treatment for adult patients with PNH - Barchart

Feb 13, 2025
pulisher
Feb 11, 2025

Novartis to buy Anthos Therapeutics in $3.1bn deal - Proactive Investors UK

Feb 11, 2025
pulisher
Feb 09, 2025

Novartis 2017 Financial Results - Novartis

Feb 09, 2025
pulisher
Feb 07, 2025

ATI Inc [ATI] Records 200-Day SMA of $59.51 - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

Taking a look at what insiders are doing to gauge the America Movil S.A.B.DE C.V. ADR (AMX)’s direction - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

Novartis AG ADR [NVS] Officer makes an insider purchase of 6,566 shares worth 0.73 million. - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

NVS’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Feb 07, 2025
pulisher
Feb 07, 2025

Novartis AG ADR (NVS) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News

Feb 07, 2025
pulisher
Feb 06, 2025

Novartis AG ADR [NVS] is 12.85% higher this YTD. Is it still time to buy? - The DBT News

Feb 06, 2025
pulisher
Feb 06, 2025

Delhi High Court grants ad interim injunction to leading pharmaceutical company NOVARTIS; restrains use of NOVITAS mark - SCC Online

Feb 06, 2025
pulisher
Feb 03, 2025

HSBC Securities downgrades Novartis AG ADR (NVS) rating to a Reduce - Knox Daily

Feb 03, 2025
pulisher
Feb 03, 2025

2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond - sharewise

Feb 03, 2025
drug_manufacturers_general MRK
$77.85
price down icon 0.19%
$273.68
price down icon 1.30%
drug_manufacturers_general NVO
$58.33
price up icon 0.43%
$104.33
price down icon 0.20%
drug_manufacturers_general SNY
$50.93
price up icon 0.06%
Kapitalisierung:     |  Volumen (24h):